Tenax Therapeutics (TENX) Expected to Announce Quarterly Earnings on Tuesday

Tenax Therapeutics (NASDAQ:TENX) is expected to issue its Q4 2025 results before the market opens on Tuesday, March 24th. Analysts expect the company to announce earnings of ($1.26) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 4:00 PM ET.

Tenax Therapeutics (NASDAQ:TENX) last announced its quarterly earnings results on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.88. On average, analysts expect Tenax Therapeutics to post $-1 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Tenax Therapeutics Stock Up 1.0%

Tenax Therapeutics stock opened at $13.98 on Tuesday. The company has a 50 day moving average of $13.38 and a 200-day moving average of $10.07. Tenax Therapeutics has a twelve month low of $4.63 and a twelve month high of $18.38. The stock has a market capitalization of $87.29 million, a PE ratio of -10.51 and a beta of 1.41.

Institutional Trading of Tenax Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Perceptive Advisors LLC acquired a new position in Tenax Therapeutics during the fourth quarter worth $5,353,000. Diadema Partners LP acquired a new stake in Tenax Therapeutics in the 4th quarter valued at $2,964,000. Sphera Funds Management LTD. acquired a new stake in Tenax Therapeutics in the 4th quarter valued at $2,317,000. Marshall Wace LLP lifted its position in Tenax Therapeutics by 68.2% during the 4th quarter. Marshall Wace LLP now owns 298,153 shares of the specialty pharmaceutical company’s stock worth $3,634,000 after buying an additional 120,944 shares in the last quarter. Finally, Woodline Partners LP bought a new stake in Tenax Therapeutics during the 3rd quarter worth about $671,000. Institutional investors own 1.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on TENX shares. Lifesci Capital raised shares of Tenax Therapeutics to a “strong-buy” rating in a research report on Thursday, March 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tenax Therapeutics in a report on Monday, December 22nd. Guggenheim lifted their price target on Tenax Therapeutics from $25.00 to $34.00 and gave the company a “buy” rating in a research note on Monday. Finally, William Blair reissued an “outperform” rating on shares of Tenax Therapeutics in a research note on Tuesday, March 10th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $27.00.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.